U.S. Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032

Nov 2022| BIS702A| BIS Research

Report Highlights

U.S. Hereditary Genetic Testing Market to Reach $29.28 Billion by 2032

Market Segmentation

Segment 1: by Product

  • Services
  • Kits
  • Consumables
  • Others

Among the product segment, the services segment in the U.S. hereditary genetic testing market occupies the largest share of the market and is expected to dominate in the coming years as well. This is because companies are actively providing services to hereditary testing laboratories in addition to providing genetic testing kits and consumables.

Segment 2: by Sample

  • Blood
  • Saliva
  • Tumor Tissue
  • Bone Marrow
  • Other Sample Types

Among the sample segment, blood samples are majorly used for conducting hereditary genetic testing in the U.S.

Segment 3: by Application Area

  • Clinical Diagnostics
  • Academics and Research
  • Drug Discovery
  • Monitoring and Screening

Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market. However, drug discovery currently occupies a relatively major share, and the share of academics and research is expected to increase in the coming years.

Recent Developments in the U.S. Hereditary Genetic Testing Market

  • On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension. This partnership with Ascension boosts access to Laboratory Corporation of America Holdings’ clinical laboratory services, analytics, and laboratory network for the Ascension-served communities, eventually enhancing productivity and healthcare services.
  • On 29 September 2022, Illumina, Inc. announced the launch of the NovaSeq X Series (NovaSeq X and NovaSeq X Plus), the new production-scale sequencers. These production-scale sequencers are designed to enable faster, more powerful, and more sustainable sequencing. With the aid of this technology, the company aims to lead advancing genomic research and clinical understanding, ultimately improving patient lives.
  • On 14 September 2022, Qiagen, N.V. entered into a partnership with Neuron23 in order to provide a companion diagnosis for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's disease.

Demand Drivers and Restraints

Following are the demand drivers identified for the U.S. hereditary genetic testing market

  • Growing Demand for Early and Preventive Care
  • Increasing Number of New Cases of Cancer Indications and Associated Disease Burden
  • Increasing Technological Advancement Resulting in Improved Outcome
  • Rising Prevalence of Genetic Disorders

The U.S. hereditary genetic testing market is expected to face some challenges due to the following reasons

  • Hesitation Among Patients Toward Genetic Testing
  • High Capital Requirement Hampering the Expansion
  • Lack of Accurate Risk Assessment in Neuromuscular Disorders

How can this report add value to an organization?

Product/Innovation Strategy: The report highlights the approaches being considered for making the test reach a larger population. The companies are incorporating data analytics and various software applications that can help them in fetching a more accurate result from a large genome data bank available to the company. The report also provides an epidemiology forecast of selected cancer indications across different regions of the U.S., which again helps in assessing the expected market opportunity for hereditary genetic testing.

Growth/Marketing Strategy: The several growth strategies identified in the report include increased focus toward technological advancement in making the tests more accurate as well as quick, making the tests more accessible to a broader population either by reducing the price or by getting them approved for reimbursement.

Competitive Strategy: The report provides insight into the existing competition in the U.S. hereditary genetic testing market. The leading players, along with their contributions and market shares, have been identified and profiled in the report. Moreover, a detailed competitive benchmarking of the players operating in the U.S. hereditary genetic testing market has been included to help the reader understand how players stand against each other, presenting a clear market landscape. The report also highlights the key activities the companies were engaged in in the last three years. This will additionally help in evaluating the dynamics of the market with respect to growth and sustainability in the business.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2032
Base year market size $8.56 Billion in 2022
Market size forecast $29.28 Billion by 2032
Growth rate 13.09%
Units considered $ Millions
Segments covered by Product, by Sample, by Application Area
Industry covered BIS Healthcare
Companies studied
  • Color Health, Inc.
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ambry Genetics
  • BGI
  • Eurofins Scientific SE
  • Illumina, Inc.
  • Invitae Corporation
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.
  • Fulgent Genetics, Inc.
  • Exact Sciences Corporation
  • Guardant Health
  • Laboratory Corporation of America Holdings
  • PerkinElmer Inc.
  • Natera, Inc.

U.S. Hereditary Genetic Testing Market Overview

The U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is expected to grow with a CAGR of 13.09% and reach $29.28 billion by 2032. The growth in the U.S. hereditary genetic testing market is expected to be driven by growing demand for early and preventive care and increasing prevalence and associated disease burden related to various cancer, among others.

Market Lifecycle Stage

The U.S. hereditary genetic testing market appears to be highly dynamic at the moment, with companies focusing on the adoption of advanced technologies in order to cater to the demand of processing large data as well as efforts to make genetic testing reach a larger population.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The U.S. hereditary genetic testing market in 2021 was dominated by the following key players with a total market share of 51.45%:

  • Laboratory Corporation of America Holdings
  • Quest Diagnostics Incorporated
  • F. Hoffmann-La Roche Ltd.

The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

  • BGI
  • Illumina, Inc.
  • Eurofins Scientific SE
  • Myriad Genetics, Inc.
  • Natera, Inc.

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.

With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.

Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research
Price: $5250

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.